<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05076435</url>
  </required_header>
  <id_info>
    <org_study_id>RECEM0001</org_study_id>
    <secondary_id>2021-000224-35</secondary_id>
    <secondary_id>1-10-72-163-21</secondary_id>
    <nct_id>NCT05076435</nct_id>
  </id_info>
  <brief_title>Restrictive Fluid Administration vs. Standard of Care in Emergency Department Sepsis Patients</brief_title>
  <acronym>REFACED Sepsis</acronym>
  <official_title>Restrictive Fluid Administration vs. Standard of Care in Emergency Department Sepsis Patients - a Multicenter, Randomized Clinical Feasibility Trial (REFACED Sepsis)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Marie Kristine Jessen, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Aarhus University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Viborg Regional Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Randers Regional Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an investigator-initiated, multicenter, randomized, parallel-group, open-labeled,&#xD;
      feasibility trial investigating volumes of fluid within 24 hours in 124 patients with sepsis&#xD;
      allocated to two different IV fluid regimens enrolled at three emergency departments in&#xD;
      Central Region Denmark. The primary outcome is total intravenous, crystalloid fluid volume&#xD;
      within 24 hours and key secondary outcomes include protocol violations, total fluids&#xD;
      (intravenous and oral) within 24 hours, SAEs/SUSARs, and inhospital-, 30- and 90-day&#xD;
      mortality.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BACKGROUND:&#xD;
&#xD;
      Sepsis is common in emergency department (ED) patients. Traditionally, intravenous (IV)&#xD;
      fluids are used to optimise the circulation, and the use of higher volumes is recommended by&#xD;
      international guidelines, but there are no recommendations for sepsis without hypotension or&#xD;
      shock. Studies in septic shock seem to favour fluid restriction. Whether this is true in&#xD;
      sepsis without hypotension/shock is unknown.&#xD;
&#xD;
      OBJECTIVES:&#xD;
&#xD;
      The aim of the REFACED Sepsis trial is to test if an IV fluid restrictive protocol in ED&#xD;
      patients with sepsis is feasible, i.e., if the protocol decreases the IV fluid volumes&#xD;
      administered.&#xD;
&#xD;
      DESIGN:&#xD;
&#xD;
      REFACED Sepsis is a multicenter, randomized, parallel-group, open-labeled, feasibility trial&#xD;
&#xD;
      POPULATION:&#xD;
&#xD;
      ED patients with sepsis expected to be admitted for ≥ 24 hours&#xD;
&#xD;
      EXPERIMENTAL INTERVENTION:&#xD;
&#xD;
      In the IV fluid restriction group no IV fluids should be given unless one of the below&#xD;
      mentioned occurs;&#xD;
&#xD;
      A fluid bolus of 250 ml isotonic crystalloid may be given within 15 minutes if one of the&#xD;
      following occurs (hypoperfusion criteria):&#xD;
&#xD;
        -  Lactate concentration ≥ 4 mmol/l (arterial or venous blood gas/blood sample)&#xD;
&#xD;
        -  Hypotension (systolic BP &lt; 90 mmHg)&#xD;
&#xD;
        -  Mottling beyond edge of kneecap (i.e., Mottling score &gt;2)53&#xD;
&#xD;
        -  Severe oliguria, i.e., diuresis &lt; 0.1 ml/kg/h, during the first 4 hours of admission&#xD;
&#xD;
      All patients will be ensured min. 1 L of oral/intravenous fluids in 24 hours and electrolytes&#xD;
      can be corrected.&#xD;
&#xD;
      CONTROL INTERVENTION:&#xD;
&#xD;
      In the usual care group there will be no upper limit for the use of IV fluids.&#xD;
&#xD;
      OUTCOMES:&#xD;
&#xD;
      The primary outcome is 24-hour intravenous crystalloid fluid administration. Key secondary&#xD;
      outcomes are: Feasibility measures: Number of patients with major protocol violations, Number&#xD;
      of patients screened vs included, Time from admission to inclusion, Number of patients lost&#xD;
      to follow up in terms of 24-hour fluids, Accumulated serious adverse reactions and events&#xD;
      (SAEs + Suspected Unexpected Serious Adverse Reaction (SUSARs)) within 48 hours in-hospital,&#xD;
      Total fluids (oral and intravenous) at 24 hours,&#xD;
&#xD;
      TRIAL-SIZE:&#xD;
&#xD;
      124 patients will be randomized to restrictive fluid administration or usual care within 24&#xD;
      hours of randomization&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 3, 2021</start_date>
  <completion_date type="Anticipated">April 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 30, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>24-hour crystalloid iv. fluids</measure>
    <time_frame>24 hours from randomization</time_frame>
    <description>total amount of all administered intravenous, crystalloid fluids within 24 hours of randomization</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Protocol violations</measure>
    <time_frame>24 hours from randomization</time_frame>
    <description>Feasibility measure: Number of patients with major protocol violations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Screened-vs.-randomized-ratio</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Feasibility measure: Number of patients screened vs included</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to inclusion</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Feasibility measure: Time from admission to inclusion/randomization (hours)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lost-to-follow-up-rate</measure>
    <time_frame>24 hours from randomization</time_frame>
    <description>Feasibility measure: Number of patients lost to follow up in terms of 24-hour fluids</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulated serious adverse reactions (SARs + SUSARs)</measure>
    <time_frame>7 days from randomization</time_frame>
    <description>Feasibility measure: Accumulated serious adverse reactions and events (SAEs + SARs+ SUSARs) within 7 days in-hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total 24-hour fluids</measure>
    <time_frame>24 hours from randomization</time_frame>
    <description>Total fluids (oral and intravenous) at 24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>Total of 90-days</time_frame>
    <description>In-hospital, 30- and 90-days mortality</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">124</enrollment>
  <condition>Sepsis</condition>
  <arm_group>
    <arm_group_label>Restrictive fluid administration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>No IV fluids unless one of the extenuating circumstances occur;&#xD;
In case of severe hypoperfusion or severe circulatory impairment defined by either: 1) Lactate≥4 mmol/L, 2) Hypotension (systolic BP &lt; 90 mmHg), 3) Mottling beyond the kneecap (mottling score &gt;2) OR 4) Urinary output&lt;0.1 mL/kg bodyweight/h (only in the first 4hrs after randomization) then a bolus of 250 ml of IV crystalloid solution may be given followed by re-evaluation&#xD;
In case of overt fluid losses (e.g. vomiting, large aspirates,) IV fluid may be given to correct for the loss, but not above the volume lost.&#xD;
In case the oral/enteral route for water or electrolyte solutions is contraindicated or has failed, IV fluids may be given to:&#xD;
Correct dehydration or electrolyte deficiencies Ensure a total fluid input of 1 L in 24hrs&#xD;
IV fluids may be given as carrier for medication, but with lowest possible volume</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual care (standard care)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>There will be no upper limit for the use of either IV or oral/enteral fluids&#xD;
IV fluids should be given in the case of hypoperfusion or circulatory impairment and should be continued as long as hemodynamic variables improve including static or dynamic variable(s) as chosen by the clinicians. These criteria are based on the Surviving Sepsis Campaign guideline.&#xD;
IV fluids should be given as maintenance if the ICU has a protocol recommending maintenance fluid&#xD;
IV fluids should be given to substitute expected or observed loss, dehydration or electrolyte derangements</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isotonic crystalloids</intervention_name>
    <description>Types of fluids in both intervention groups:&#xD;
Fluids used for electrolyte disturbances: Fluids should be chosen to substitute the specific deficiency&#xD;
Fluids given to substitute overt loss: Isotonic crystalloids are to be used. If large amounts of ascites are tapped, then human albumin may be used.&#xD;
Blood products are only to be used on specific indications including severe bleeding, severe anaemia and prophylactic in case of severe coagulopathy.</description>
    <arm_group_label>Restrictive fluid administration</arm_group_label>
    <arm_group_label>Usual care (standard care)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: All of the below must be fulfilled:&#xD;
&#xD;
          1. Unplanned emergency department admission&#xD;
&#xD;
          2. Age ≥ 18 years&#xD;
&#xD;
          3. Sepsis defined as&#xD;
&#xD;
               1. suspected infection by the treating clinician AND&#xD;
&#xD;
               2. blood cultures drawn AND&#xD;
&#xD;
               3. IV antibiotics administered or planned AND&#xD;
&#xD;
               4. An infection related increase of SOFA*-score ≥ 2 from baseline&#xD;
&#xD;
          4. Expected hospital stay &gt; 24 hours as deemed by treating clinician&#xD;
&#xD;
               -  Sequential Organ Failure Assessment (SOFA) Score&#xD;
&#xD;
        Further more the patient must fulfill criteria for enrollment in an acute study according&#xD;
        to Danish law&#xD;
&#xD;
        Exclusion Criteria: We will exclude patients fulfilling any of following exclusion&#xD;
        criteria:&#xD;
&#xD;
          1. ≥ 500 ml of fluids given prior to randomization&#xD;
&#xD;
          2. Invasively ventilated or vasopressors initiated at the time of screening&#xD;
&#xD;
          3. Known or suspected severe bleeding judged by the treating clinician&#xD;
&#xD;
          4. Known or suspected pregnancy (women aged &lt;45 years will have a pregnancy test&#xD;
             performed before enrollment)&#xD;
&#xD;
          5. Prior enrollment in the trial&#xD;
&#xD;
          6. Patients, who the clinician expect not to survive the next 24-hours&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marie K Jessen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Research Center for Emergency Medicine, Department of Clinical Medicine, Aarhus University and Aarhus University Hospital, Denmark</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marie K Jessen, MD</last_name>
    <phone>004525333286</phone>
    <email>marie.jessen@rm.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hans Kirkegaard, MD PhD DMSc</last_name>
    <phone>00457846 6662</phone>
    <email>hanskirk@rm.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Emergency Medicine, Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <state>Central Denmark Region</state>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie K Jessen, MD</last_name>
      <phone>+45-25333286</phone>
      <email>marie.jessen@rm.dk</email>
    </contact>
    <contact_backup>
      <last_name>Ranva E Hassel, MD</last_name>
      <email>ranva.hassel@auh.rm.dk</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Department of Emergency Medicine, Regional Hospital Randers</name>
      <address>
        <city>Randers</city>
        <state>Central Denmark Region</state>
        <zip>8930</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wazhma Hayeri, MD</last_name>
      <email>wazhay@rm.dk</email>
    </contact>
    <contact_backup>
      <last_name>Marie K Jessen, MD</last_name>
      <email>marie.jessen@rm.dk</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Department of Emergency Medicine, Regional Hospital Viborg</name>
      <address>
        <city>Viborg</city>
        <state>Central Denmark Region</state>
        <zip>8800</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Peter Kristensen, MD</last_name>
      <email>petkre@rm.dk</email>
    </contact>
    <contact_backup>
      <last_name>Marie K Jessen, MD</last_name>
      <email>marie.jessen@rm.dk</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 11, 2021</study_first_submitted>
  <study_first_submitted_qc>September 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 13, 2021</study_first_posted>
  <last_update_submitted>November 15, 2021</last_update_submitted>
  <last_update_submitted_qc>November 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Aarhus</investigator_affiliation>
    <investigator_full_name>Marie Kristine Jessen, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Sepsis</keyword>
  <keyword>Hypotension</keyword>
  <keyword>IV fluid therapy</keyword>
  <keyword>Fluid resuscitation</keyword>
  <keyword>Emergency Department</keyword>
  <keyword>Crystalloids</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
    <mesh_term>Emergencies</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

